Corcept Concludes Patient Enrollment In Corlux Phase 3 Trial
The FDA has indicated that the single 50-patient open-label Phase 3 study of Corlux, which is being conducted at 20 medical facilities throughout the US, may provide a
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.